US OptionsDetailed Quotes

CERS241018P5000

Watchlist

3.23
0.000.00%

15min DelayClose Sep 27 15:59 ET

0.00High0.00Low

Cerus Stock Discussion

Trytosaveabit

Aug 1 15:20

$Cerus (CERS.US)$ Earnings Flash (CERS) CERUS CORPORATION Reports Q2 Revenue $50.5M, Vs. Street Est of $42.5M
Cerus Outlook FY Revenue USD 175-178 Million

Trytosaveabit

May 14 18:30

Insider buy

$Cerus (CERS.US)$ Director Shan Hua purchased 2,500 shares of common stock on May 13, 2024 at an average price of $1.9899 for a total value of $4,974.75.

hard-working Camel_4

Mar 26 08:11

$Cerus (CERS.US)$ Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life

hard-working Camel_4

Mar 19 10:24

$Cerus (CERS.US)$ 🚀🚀🚀

hard-working Camel_4

Mar 19 08:08

$Cerus (CERS.US)$ Cerus Announces Positive Results For Phase 3 Trial Of Intercept Blood System

Trytosaveabit

Mar 19 07:51

$Cerus (CERS.US)$ That gap at 2.11 almost filled!

Boom!

$Cerus (CERS.US)$ Cerus Corporation Announces Its ReCePI Phase 3 Trial Of INTERCEPT Blood System Met Its Primary Efficacy Endpoint; Safety Endpoint Of The Proportion Of Patients With Any Related Treatment-Emergent Adverse Events Within 28 Days Of Last Transfusion Was Not Significantly Different For Intercept RBCs

Moomoo AI

Feb 7 04:41

Despite recent uplift, the business needs to justify a higher price. Market focus is on revenue growth due to unprofitability. Fast revenue growth doesn't guarantee profits, and if cash is low, capital may need to be raised. Investors should note the 3 warning signs with Cerus.

Cerus (NASDAQ:CERS) Shareholders Are up 23% This Past Week, but Still in the Red Over the Last Three Years

Moomoo AI

Jan 21 15:54

Cantor Fitzgerald sees AVITA's superior growth and high gross margins as reasons for a premium. The firm also sees potential in Pacific Biosciences and AxoGen, and expects positive share price appreciation for Exagen and NeuroPace. A significant catalyst for Nyxoah's stock is anticipated with upcoming DREAM study data.

Cantor Picks RCEL as Best 2024 Medtech Idea; Bullish on PACB, AXGN, CERS

No comment yet